| 2012 |
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. February 2012;27(2):243-254. |
24 |
18 |
| 2020 |
Woods GN, Ewing SK, Sigurdsson S, Kado DM, Eiriksdottir G, Gudnason V, Hue TF, Lang TF, Vittinghoff E, Harris TB, Rosen C, Xu K, Li X, Schwartz AV. Greater bone marrow adiposity predicts bone loss in older women. J Bone Miner Res. February 2020;35(2):326-332. |
3 |
2 |
| 2022 |
Woods GN, Ewing SK, Schafer AL, Gudnason V, Sigurdsson S, Lang T, Hue TF, Kado DM, Vittinghoff E, Rosen C, Li X, Schwartz AV. Saturated and unsaturated bone marrow lipids have distinct effects on bone density and fracture risk in older adults. J Bone Miner Res. April 2022;37(4):700-710. |
1 |
0 |
| 2005 |
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEJM. August 11, 2005;353(6):555-565. |
34 |
26 |
| 2007 |
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. May 3, 2007;356(18):1809-1822. |
90 |
66 |